Also, Memorial Sloan Kettering Cancer Center’s mathematical optimisation engine will be co-developed as part of an Australian AI cancer treatment workflow platform.
BlinkLab bags $13M for autism diagnostic AI
ASX-listed diagnostics AI company BlinkLab has raised A$17.5 million ($12.6 million) through an oversubscribed placement to support regulatory and commercial work for its AI-powered diagnostic aid for autism.
Based on a company disclosure, the proceeds will fund BlinkLab’s pivotal trial of the BlinkLab Dx1 to secure the United States Food and Drug Administration’s 510(k) clearance, as well as regulatory work to obtain CE marking and EU MDR compliance.
A portion of the new funds will also go to US clinical studies for BlinkLab Dx2, an ADHD diagnostic adjunct that uses the same smartphone-based platform and AI infrastructure.
Lumonus, MSK partner on radiotherapy planning
Lumonus is collaborating with Memorial Sloan Kettering Cancer Center to integrate the latter’s mathematical optimisation engine into the Australian startup’s radiation oncology workflow and treatment planning platform.
The New York City-based cancer centre’s ECHO uses constraint-based mathematical methods to compute radiation therapy treatment plans from first principles. Based on a media statement, Lumonus will license and co-develop the technology into its radiation oncology platform.
The collaboration will also support joint research on automated radiation therapy treatment planning.
NSW funds maternal AI development
The New South Wales government has awarded A$7.4 million ($5.3 million) through its Medical Devices Fund to four medtech companies, including Baymatob, which is developing an AI-powered maternal-foetal early warning platform.
Baymatob will use its share of the funding to complete the development of Oli, which is designed to warn clinicians of treatable complications in pregnancy and labour, including postpartum haemorrhage, stillbirth, and uterine rupture.
Since its first round in 2012, the NSW government’s Medical Devices Fund has awarded more than A$102 million ($74 million) to 56 medical technologies, supporting more than 260 clinical trials and 47 market entries.
The other latest fund recipients are Roam Technologies for a portable oxygen concentrator, Amazing Gut for a wireless home-use biofeedback device for bowel function, and Kraken Coding for a clinical decision-support platform that generates patient-specific treatment and prioritisation pathways.
